(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
-1.86% $ 5.27
Live Chart Being Loaded With Signals
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health...
Stats | |
---|---|
Dzisiejszy wolumen | 172 513 |
Średni wolumen | 110 098 |
Kapitalizacja rynkowa | 1.87B |
EPS | $-0.120 ( 2023-11-08 ) |
Następna data zysków | ( $-0.100 ) 2024-06-10 |
Last Dividend | $0.0722 ( 2019-01-11 ) |
Next Dividend | $0 ( N/A ) |
P/E | -21.08 |
ATR14 | $0.00700 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2018-10-22 | Anderson Mark Monroe | Buy | 100 000 | Stock Option (right to buy) |
2018-10-22 | Anderson Mark Monroe | Buy | 0 | |
2018-08-13 | Smith Scott Clifford | Buy | 100 000 | Stock Option (right to buy) |
2018-08-13 | Smith Scott Clifford | Buy | 0 | |
2018-08-13 | Laffer Arthur B | Buy | 100 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
0.00 |
Last 13 transactions |
Buy: 500 392 | Sell: 1 057 |
Wolumen Korelacja
Eaton Vance Ohio Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
SOJD | 0.872 |
RYB | 0.869 |
WPM | 0.869 |
NEU | 0.869 |
KBH | 0.867 |
SAP | 0.851 |
GLDM | 0.85 |
SGOL | 0.85 |
OUNZ | 0.849 |
BAR | 0.849 |
10 Najbardziej negatywne korelacje | |
---|---|
DZZ | -0.856 |
EQNR | -0.84 |
GLL | -0.836 |
DGZ | -0.835 |
EBF | -0.829 |
DBMF | -0.817 |
RPM | -0.814 |
PKO | -0.814 |
PCQ | -0.814 |
KMLM | -0.809 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Eaton Vance Ohio Korelacja - Waluta/Towar
Eaton Vance Ohio Finanse
Annual | 2023 |
Przychody: | $781.43M |
Zysk brutto: | $175.05M (22.40 %) |
EPS: | $-0.470 |
FY | 2023 |
Przychody: | $781.43M |
Zysk brutto: | $175.05M (22.40 %) |
EPS: | $-0.470 |
FY | 2022 |
Przychody: | $751.45M |
Zysk brutto: | $174.07M (23.16 %) |
EPS: | $-0.990 |
FY | 2021 |
Przychody: | $618.03M |
Zysk brutto: | $151.54M (24.52 %) |
EPS: | $0.650 |
Financial Reports:
No articles found.
Eaton Vance Ohio Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0561 | 2001-01-05 |
Last Dividend | $0.0722 | 2019-01-11 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 221 | -- |
Total Paid Out | $14.33 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.4 | -- |
Div. Sustainability Score | 3.29 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 1.328 | -- |
Year | Amount | Yield |
---|---|---|
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $1.008 | 24.50% |
2005 | $1.024 | 55.70% |
2006 | $0.704 | 34.50% |
2007 | $0.650 | 153.20% |
2008 | $0.738 | 177.80% |
2009 | $0.814 | 150.70% |
2010 | $0.966 | 61.90% |
2011 | $0.857 | 41.40% |
2012 | $0.832 | 54.40% |
2013 | $0.793 | 45.30% |
2014 | $0.732 | 28.90% |
2015 | $0.732 | 32.70% |
2016 | $0.570 | 25.20% |
2017 | $0.576 | 14.20% |
2018 | $0.495 | 6.05% |
2019 | $0.0722 | 0.71% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
ORC | Dividend Royal | 2023-11-29 | Monthly | 12 | 9.23% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.111 | 1.500 | -2.22 | -3.33 | [0 - 0.5] |
returnOnAssetsTTM | -0.0367 | 1.200 | -1.224 | -1.469 | [0 - 0.3] |
returnOnEquityTTM | -0.0731 | 1.500 | -1.923 | -2.88 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.944 | 0.800 | 5.28 | 4.22 | [1 - 3] |
quickRatioTTM | 1.740 | 0.800 | 4.47 | 3.58 | [0.8 - 2.5] |
cashRatioTTM | 1.100 | 1.500 | 5.00 | 7.50 | [0.2 - 2] |
debtRatioTTM | 0.272 | -1.500 | 5.46 | -8.19 | [0 - 0.6] |
interestCoverageTTM | -6.79 | 1.000 | -3.63 | -3.63 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.192 | 2.00 | 9.94 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -1.029 | 2.00 | -0.514 | -1.029 | [0 - 20] |
debtEquityRatioTTM | 0.559 | -1.500 | 7.76 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.226 | 1.000 | 9.57 | 9.57 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0826 | 1.000 | -3.65 | -3.65 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0542 | 1.000 | -0.810 | -0.810 | [0.2 - 2] |
assetTurnoverTTM | 0.330 | 0.800 | -1.130 | -0.904 | [0.5 - 2] |
Total Score | 3.29 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -10.26 | 1.000 | -1.137 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0731 | 2.50 | -1.236 | -2.88 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.029 | 2.00 | -0.343 | -1.029 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.192 | 2.00 | 9.94 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.494 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0447 | 1.000 | -1.383 | 0 | [0.1 - 0.5] |
Total Score | -0.630 |
Eaton Vance Ohio
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej